Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2016-01-28 Board/Management Inform…
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
FORM 8-K AMENDMENT NO 1
Board/Management Information Classification · 95% confidence The document is a Form 8-K Amendment (8-K/A) filed with the SEC, specifically a current report amendment. It updates a prior filing regarding the appointment date of a director. The content focuses on management changes (director appointment date correction). The document length is short (2091 characters) and it is not a full report but an amendment to a regulatory filing. The key section is Item 5.02, which relates to departure or appointment of directors or officers. This fits the category of Board/Management Information (MANG).
2016-01-28 English
FORM 4 SUBMISSION
Director's Dealing
2016-01-28 English
FORM 3 SUBMISSION
Director's Dealing
2016-01-28 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically announces the appointment of a new director to the Board of Directors, including details about the individual's background and compensation. This matches the description of Board/Management Information filings, which cover announcements of changes in the company's board or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other type of filing. Therefore, the appropriate classification is MANG (Board/Management Information). The document length and content support a high confidence in this classification.
2016-01-27 English
TAPIMMUNE INC.
Major Shareholding Notification
2016-01-19 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content includes details about unregistered sales of equity securities (warrant exercises and resulting share issuance), press releases about presentations and FDA orphan drug designation, and exhibits containing press releases. There are no comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy, or governance report. It is a regulatory filing reporting material corporate events and disclosures as required by the SEC. The length is 4246 characters, which is consistent with a typical 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-12-11 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.